- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: compound 25 [PMID: 21028894]
Compound class: Synthetic organic
Comment: Henatinib is a kinase inhibitor with some selectivity for VEGFR2 (KDR). Discovery was reported by Cho et al. (2010), the same article that disclosed famitinib . The name henatinib is linked to the structure of 'compound 25' in the article by Gu et al. (2010) that describes a method for detecting and quantifying henatinib maleate in rat plasma .
Henatinib is a 'pseudo' INN, that takes the form of an INN for a kinase inhibitor, but has not been submitted to the World Health Organisation for ratification.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|No information available.|
|Summary of Clinical Use|
|A Phase 1 clinical study of henatinib in patients with advanced solid tumours (NCT01416623) was terminated. The reasons for discontinuing the trial are undisclosed.|
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT01416623||A Phase I Study of Henatinib in Patients With Advanced Solid Malignancies||Phase 1 Interventional||Jiangsu HengRui Medicine Co., Ltd.|